Demegen Overview
- Founded
- 1992

- Status
- Acquired/Merged
- Latest Deal Type
- M&A
- Financing Rounds
- 4
- Investments
- 1
Demegen General Information
Description
Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fungi. The company develops products for the treatment of dermatological, vaginal, respiratory, ophthalmic and oral diseases with the peptides bind to and kill harmful microorganisms.
Contact Information
- 100 Technology Drive
- Suite 440B
- Pittsburgh, PA 15219
- United States
Demegen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.
Request a free trialDemegen Comparisons
Industry
000000 0
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialDemegen Competitors (4)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Myriad Genetics | Corporation | Salt Lake City, UT | 0000 | 00000 | 000000 - 000 | 00000 |
00000000000 | Corporation | Aurora, CO | 0 | 0000000000 | ||
00000000 000000000 | Venture Capital-Backed | Wuxi, China | 00000 | 00000000000 | 00000 | |
0000000 0000000000 | Venture Capital-Backed | Boston, MA | 00 | 000.00 | 00000000000 | 000.00 |
Demegen Executive Team (1)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Richard Ekstrom | Chief Executive Officer |
Demegen Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.
Request a free trialDemegen Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000000 | 01-Jan-2001 | 000000000000000000 | Other Pharmaceuticals and Biotechnology |